Is olaparib cost effective in metastatic castration-resistant prostate cancer patients with at least one favorable gene mutation in BRCA1, BRCA2 or ATM?

References

• 1. International Agency for Research on Cancer. Global cancer observatory. https://gco.iarc.fr/today/home
  Google Scholar
• 2. SEER Cancer Statistics Review, 1975–2017. National Cancer Institute, MD, USA, https://seer.cancer.gov/csr/1975_2017/results_merged/topic_survival.pdf
  Google Scholar
• 3. De Bono J, Mateo J, Fizazi K et al. Olaparib for metastatic castration-resistant prostate cancer. N. Engl. J. Med. 382(22), 2091–2102 (2020).
  MedlineGoogle Scholar
• 4. Hussain M, Mateo J, Fizazi K et al. Survival with olaparib in metastatic castration-resistant prostate cancer. N. Engl. J. Med. 383(24), 2345–2357 (2020).
  Medline CASGoogle Scholar
• 5. Pritchard CC, Mateo J, Walsh MF et al. Inherited DNA-repair gene mutations in men with metastatic prostate cancer. N. Engl. J. Med. 375(5), 443–453 (2016).
  Medline CASGoogle Scholar
• 6. Blackford AN, Jackson SP. ATM, ATR, and DNA-PK: the trinity at the heart of the DNA damage response. Mol. Cell 66(6), 801–817 (2017).
  Medline CASGoogle Scholar
• 7. Castro E, Goh C, Olmos D et al. Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. J. Clin. Oncol. 31(14), 1748–1757 (2013).
  Medline CASGoogle Scholar
• 8. Mateo J, Carreira S, Sandhu S et al. DNA-repair defects and olaparib in metastatic prostate cancer. N. Engl. J. Med. 373(18), 1697–1708 (2015).
  Medline CASGoogle Scholar
• 9. Mateo J, Nuria P, Bianchini D et al. Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, Phase 2 trial. Lancet Oncol. 21(1) 162–174 (2020).
  Medline CASGoogle Scholar
• 10. Robson M, Im SA, Senkus E et al. Olaparib for metastatic breast cancer in patients with a germline BRCA Mutation. N. Engl. J. Med. 377(6), 523–533 (2017).
  Medline CASGoogle Scholar
• 11. Moore K, Colombo N, Scambia G et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N. Engl. J. Med. 379(26), 2495–2505 (2018).
  Medline CASGoogle Scholar
• 12. Golan T, Hammel P, Reni M et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N. Engl. J. Med. 381(4), 317–327 (2019).
  Medline CASGoogle Scholar
• 13. NCCN Clinical Practice Guidelines in Oncology, Prostate Cancer, Version 3.2020. http://NCCN.org
  Google Scholar
• 14. Mariotto AB, Robin Yabroff K, Shao Y, Feuer EJ, Brown ML. Projections of the cost of cancer care in the United States: 2010–2020. J. Natl Cancer Inst. 103(2), 117–128 (2011).
  MedlineGoogle Scholar
• 15. Wan X, Zhang Y, Tan C, Zeng X, Peng L. First-line nivolumab plus ipilimumab vs sunitinib for metastatic renal cell carcinoma: a cost–effectiveness analysis. JAMA Oncol. 5(4), 491–496 (2019).
  MedlineGoogle Scholar
• 16. Wu B, Ma F. Cost–effectiveness of adding atezolizumab to first-line chemotherapy in patients with advanced triple-negative breast cancer. Ther. Adv. Med. Oncol. 12, 12 (2020).
  Google Scholar
• 17. Guyot P, Ades AE, Ouwens MJNM, Welton NJ. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med. Res. Methodol. 12, 9 (2012).
  MedlineGoogle Scholar
• 18. Truven Health Analytics, IBM Watson. Micromedex RED BOOK Database. http://truvenhealth.com/Products/Micromedex/Product-Suites/Clinical-Knowledge/RED-BOOK
  Google Scholar
• 19. Ramamurthy C, Handorf EA, Correa AF, Beck JR, Geynisman DM. Cost–effectiveness of abiraterone versus docetaxel in the treatment of metastatic hormone naive prostate cancer. Urol. Oncol. 37(10), 688–695 (2019).
  MedlineGoogle Scholar
• 20. University of Pittsburgh Medical Center. Clinical diagnostic laboratory fee schedule. (2020). https://www.upmc.com/-/media/upmc/healthcare-professionals/physicians/documents/lab-fee-schedule.pdf
  Google Scholar
• 21. Centers for Medicare & Medicaid Services. Physician fee schedule. https://www.cms.gov/apps/physician-fee-schedule/
  Google Scholar
• 22. Healthcare Cost and Utilization Project. Free health care statitics. https://hcupnet.ahrq.gov/#setup
  Google Scholar
• 23. Foundation Medicine Products & Services Introduction. https://www.foundationmedicine.com/
  Google Scholar
• 24. Cynthia L, Gong JWH. Cost–effectiveness analysis of abiraterone and sipuleucel-T in asymptomatic metastatic castration-resistant prostate cancer. J. Natl Compr. Canc. Netw. 12, 10 (2014).
  MedlineGoogle Scholar
• 25. Lu P, Liang W, Li J et al. A cost–effectiveness analysis: first-line avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. Front. Pharmacol. 11, 619 (2020).
  MedlineGoogle Scholar
• 26. Barqawi YK, Borrego ME, Roberts MH, Abraham I. Cost–effectiveness model of abiraterone plus prednisone, cabazitaxel plus prednisone and enzalutamide for visceral metastatic castration resistant prostate cancer therapy after docetaxel therapy resistance. J. Med. Econ. 22(11), 1202–1209 (2019).
  MedlineGoogle Scholar
• 27. Doyle S, Lloyd A, Walker M. Health state utility scores in advanced non-small cell lung cancer. Lung Cancer 62(3), 374–380 (2008).
  MedlineGoogle Scholar
• 28. Nafees B, Stafford M, Gavriel S, Bhalla S, Watkins J. Health state utilities for non small cell lung cancer. Health Qual. Life Outcomes 6, 84 (2008).
  MedlineGoogle Scholar
• 29. Welk B, Isaranuwatchai W, Krassioukov A, Husted Torp L, Elterman D. Cost–effectiveness of hydrophilic-coated intermittent catheters compared with uncoated catheters in Canada: a public payer perspective. J. Med. Econ. 21(7), 639–648 (2018).
  MedlineGoogle Scholar
• 30. U.S. Bureau of Labor Statistics. BLS all urban consumers (current series) – (Consumer Price Index – CPI). https://www.bls.gov/data/
  Google Scholar
• 31. The IQVIA Institute. Global oncology trends. https://www.iqvia.com/insights/the-iqvia-institute/reports/global-oncology-trends-2019
  Google Scholar
• 32. Household income: 2018. American Community Survey Briefs. https://www.census.gov/content/dam/Census/library/publications/2019/acs/acsbr18-01.pdf
  Google Scholar
• 33. Household income: American community survey briefs. https://www.census.gov/programs-surveys/acs/data/summary-file.html
  Google Scholar
• 34. Saito S, Nakazawa K, Nagahashi M, Ishikawa T, Akazawa K. Cost–effectiveness of BRCA1/2 mutation profiling to target olaparib use in patients with metastatic breast cancer. Per. Med. 16(6), 439–448 (2019).
  CASGoogle Scholar
• 35. Zhong L, Tran AT, Tomasino T, Nugent E, Smith JA. Cost–effectiveness of niraparib and olaparib as maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer. J. Manag. Care Spec. Pharm. 24(12), 1219–1228 (2018).
  MedlineGoogle Scholar
• 36. Wu B, Shi L. Cost–effectiveness of maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. J. Natl Compr. Canc. Netw. 18(11), 1528–1536 (2020).
  MedlineGoogle Scholar
• 37. Antonarakis ES, Lu C, Wang H et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N. Engl. J. Med. 371(11), 1028–1038 (2014).
  MedlineGoogle Scholar